AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19217019
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.5 mg)
Trial: 8983763
Drug: Cordaphene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordaphene (30 mg)
Trial: 8983763
Drug: Diltiazeme (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazeme (180 mg)
Trial: 12742289
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (CAs)
Trial: 2153475
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (10 mg/kg bolus followed by 2 mg/kg/hr infusion)
Trial: 30076173
Drug: Conventional front-line
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional front-line induction chemotherapy (3+7 daunorubicin+cytarabine)
Trial: 28628374
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic supplement (GeriLact; n = 25)
Trial: 28475373
Drug: Lurasidone 40
RxNorm normalized name: lurasidone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 40 mg/day
Trial: 23421963
Drug: Lurasidone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (all doses)
Trial: 17174639
Drug: Aspirin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50 mg) and dipyridamole / Placebo
Trial: 12105162
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg allopurinol daily for 1 month
Trial: 10337432
Drug: Emedastine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine 0.05% ophthalmic solution
Trial: 11158809
Drug: Ketorolac 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5% ophthalmic solution
Trial: 14609312
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (5 g of glycine, glutamine, and niacin, twice daily for 3 weeks)
Trial: 14609312
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 3 weeks)
Trial: 24741361
Drug: 4 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days of normal daily activity after 21 days of bed rest
Trial: 22512878
Drug: Intravenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glutamine (0.5 g/kg/die for 7 days)
Trial: 22512878
Drug: Normal amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal amino acid solution (same quantity for 7 days)
Trial: 6352654
Drug: Ceftazidime (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (0.5 g every 12 h)
Trial: 30233812
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Trial: 30233812
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Trial: 24131447
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prior pruritus treatment)
Trial: 22244829
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (AFP < 100 ng/mL, PRETEXT IV, vascular invasion, extra-hepatic intra-abdominal disease, metastases)
Trial: 22244829
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (PRETEXT IV, multifocal tumour, age > 5 years, AFP > 1.2 × 10(6) ng/mL)
Trial: 10432408
Drug: L-arginine (ARG)
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (ARG) supplementation (0.2 g/kg body wt/day) for six months
Trial: 2331951
Drug: Antacid gel
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid gel (buffering capacity 70 meq/10 ml)
Trial: 20570122
Drug: Genistein aglycone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein aglycone (54 mg/day)
Trial: 28241420
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg) and vitamin D3 (800 IU) - placebo
Trial: 23962782
Drug: Tele-accelerometry (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-accelerometry (monthly 6MWTs)
Trial: 1602293
Drug: Ketoprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (100 mg suppository)
Trial: 1602293
Drug: Ergotamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine (2 mg suppository)
Trial: 17441414
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with carbamylated allergoid (SLIT)
Trial: 7603217
Drug: K-Y gel
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-Y gel (placebo)
Trial: 20584525
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (1,050 mg/d of eicosapentaenoic acid (EPA) and 150 mg/d of docosahexaenoic acid (DHA))
Trial: 19861864
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two types of dates
Trial: 16903603
Drug: Red-hot needle
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Red-hot needle therapy
Trial: 8193487
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K1 (2 mg)
Trial: 1444522
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin K1 (1 mg)
Trial: 8193487
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of oral vs intramuscular vitamin K1
Trial: 31099036
Drug: Placebo (simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (simulated laser therapy)
Trial: 21656308
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg IM) and Neostigmine (1 mg IM)
Trial: 12765311
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of inhaled corticosteroids
Trial: 10872704
Drug: Warfarin (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (therapeutic INR 2.8-4.2)
Trial: 10872704
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg Aspirin daily combined with Warfarin (INR 2.0-2.5)
Trial: 1317928
Drug: Oat products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat products (3 g or more of soluble fiber)
Trial: 6469082
Drug: Pentagastrin infusion
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentagastrin infusion test with cimetidine (200 mg bolus after one hour)
Trial: 30005329
Drug: Sucralose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (200 mg)
Trial: 27285466
Drug: Apremilast 50
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 50 mg, administered twice daily for 9 doses
Trial: 27285466
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg, administered as a positive control
Trial: 19042325
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) in 9 weekly group sessions
Trial: 15277619
Drug: PCV (procarbazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV (procarbazine, 60 mg/m2 on days 8 to 21; CCNU, 110 mg/m2 on day 1; and vincristine, 1.4 mg/m2 on days 8 and 29)
Trial: 15277619
Drug: Temozolomide (TMZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (TMZ; 150 to 200 mg/m2 for 5 days every 4 weeks)
Trial: 2878131
Drug: Ileu‐ANP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileu‐ANP infusion (5 micrograms/min for 4 h)
Trial: 26774608
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg per day
Trial: 25139724
Drug: Intrauterine administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine administration of 5 cc of 2% lidocaine
Trial: 22873367
Drug: Routine fertility
RxNorm normalized name: Tests for fertility disturbances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fertility work-up with additional (SIS and) hysteroscopy with on-the-spot treatment of predefined intrauterine abnormalities
Trial: 3305118
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) 120 mg daily
Trial: 21209232
Drug: Sibutramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (15 mg oral dose)
Trial: 19591674
Drug: Active PEMF-treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PEMF-treatment for 60 days, four hours daily
Trial: 19591674
Drug: Sham-treatment for
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-treatment for 60 days, four hours daily
Trial: 7199332
Drug: Midazolam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.2 mg/kg)
Trial: 9262801
Drug: Meperidine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (2.0 mg/kg)/Promethazine (1.0 mg/kg)
Trial: 8331703
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin and Sequential compression devices
Trial: 3581737
Drug: Cefoperazone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (1 g)
Trial: 23043721
Drug: PRO+LEU (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO+LEU (20 g casein protein + 2.5 g crystalline leucine)
Trial: 23043721
Drug: PRO (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO (20 g casein protein)
Trial: 22156381
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 4 mg i.v. every 6 months for 2 years
Trial: 22156381
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day) without ZOL
Trial: 15950351
Drug: Olanzapine in
RxNorm normalized name: olanzapine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine in monotherapy (OGm)
Trial: 9649102
Drug: Thermal uterine
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal uterine balloon therapy
Trial: 7977519
Drug: Topical intravaginal
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intravaginal clindamycin (dosages not specified, administered twice daily for 5 days)
Trial: 28320484
Drug: Twice-daily control
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily control nutritional drink enriched with standard micronutrients.
Trial: 3823637
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg sublingually)
Trial: 28892807
Drug: General Osteopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Osteopathic Treatment (GOT)
Trial: 27730033
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg daily isotretinoin (Group A)
Trial: 27730033
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg alternate days isotretinoin (Group B)
Trial: 23853000
Drug: MenC-CRM glycoconjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenC-CRM glycoconjugate vaccine (CRM-group)
Trial: 23853000
Drug: Bivalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent meningococcal serogroup A/C polysaccharide vaccine (PS-group)
Trial: 23853000
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional doses of MenC vaccine (control group)
Trial: 15164106
Drug: 0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/day nonesterified, nonhydrogenated plant sterols in low-fat milk (C)
Trial: 14971151
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy including adaptation to intermittent normobaric hypoxia and medicines
Trial: 7588666
Drug: 6 microliters
RxNorm normalized name: MICROLITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 microliters 0.25% bupivacaine + 0.05 mg kg‐1 midazolam
Trial: 2278060
Drug: Oral sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sulfadoxine-pyrimethamine
Trial: 396652
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg/day, 25 mg in the morning and midday and 50 mg at bed time)
Trial: 29203731
Drug: Mechanical thrombectomy
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical thrombectomy plus rescue therapy for ICAS
Trial: 22274319
Drug: Brachytherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachytherapy with a total dose of 15Gy to point A followed by radical surgery (arm BT)
Trial: 22274319
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy with cisplatin 50 mg/m plus 5‐fluorouracil 750 mg/m at a 2‐week interval for 2 courses followed by radical surgery (arm IVCT)
Trial: 17690950
Drug: Taurine treatment
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine treatment (2 g taurine 3 times a day for three months)
Trial: 6140441
Drug: Component vaccine
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Component vaccine containing purified haemagglutinins (HAs) of Bordetella pertussis
Trial: 6140441
Drug: Conventional whole-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional whole-cell vaccine
Trial: 29626849
Drug: Nalbuphine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine at the ED95 dose (0.128 mg/kg)
Trial: 29626849
Drug: Sufentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil at an equivalent dose
Trial: 20886801
Drug: Medicated thread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicated thread moxibustion of traditional Zhuang nationality medicine
Trial: 11882622
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg/d) for up to 5 weeks
Trial: 11882622
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ACEi treatment), n=7
Trial: 7581139
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron infusion for 7 days during Bu/CY administration
Trial: 121048
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestriol + 2 mg oestradiol
Trial: 121048
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg oestriol succinate + 1 mg oestradiol
Trial: 12648884
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol
Trial: 12648884
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestradiol
Trial: 28966211
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Trial: 28966211
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PCV13 followed by PPV23 after 24 weeks (bDMARD)
Trial: 28966211
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Trial: 28966211
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PCV13 followed by PPV23 after 16 weeks (csDMARD)
Trial: 22119746
Drug: Olanzapine orally
RxNorm normalized name: Olanzapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine orally disintegrating tablet (ODT) - mean dosage 15.2 mg
Trial: 22119746
Drug: Oral standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral standard tablet (OST) - mean dosage 15.7 mg
Trial: 17584312
Drug: Prednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (2 mg/kg/day in three divided doses for 3 days)
Trial: 15020038
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg ibuprofen for 14 days
Trial: 8458362
Drug: Quinapril once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril once daily (o.d.)
Trial: 8458362
Drug: Quinapril twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril twice daily (b.i.d.)
Trial: 3535399
Drug: Carbenicillin 10
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin 10 g every 8 h plus Gentamicin 80 mg every 8 h
Trial: 3535399
Drug: Latamoxef 2
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef 2 g every 8 h
Trial: 3535399
Drug: Carbenicillin 10
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin 10 g every 8 h plus Mecillinam 800 mg every 8 h
Trial: 21212710
Drug: FEN bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEN bolus infusion + DES inhalation
Trial: 11789241
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine alone for three months.
Trial: 11789241
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy.
Trial: 11789241
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine alone.
Trial: 14533656
Drug: Medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medicines
Trial: 28994212
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alfa-2B (HDI)
Trial: 28994212
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (BCT and HDI)
Trial: 14616416
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study A)
Trial: 14616416
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study B)
Trial: 14616416
Drug: Voriconazole 200
RxNorm normalized name: voriconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 200 mg twice daily + Placebo (Study A)
Trial: 14616416
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg three times daily + Voriconazole 200 mg (Study B)
Trial: 23115322
Drug: Low-dose beta-blockers
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose beta-blockers
Trial: 30842172
Drug: Repeated-dose RSB
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated-dose RSB analgesia
Trial: 30842172
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion RSB analgesia
Trial: 21856006
Drug: Fluoroquinolone antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone antibiotics (gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%)
Trial: 15334790
Drug: Repaglinide plus
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide plus acarbose (2 mg repaglinide 15 min before breakfast followed by 100 mg acarbose with breakfast)